Trial NCT01186328

View at ClinicalTrials.gov 
Org. Study IDs: T2009-007

Last trial update was posted on 2024-02-01

MeSH Interventions

Asparaginase Cortisone Cytarabine Doxorubicin Hydrocortisone Hydrocortisone 17-butyrate 21-propionate Hydrocortisone acetate Hydrocortisone hemisuccinate Methotrexate Pegaspargase Prednisone Vincristine

MeSH Conditions

Acute Disease Leukemia Leukemia, Lymphoid Precursor Cell Lymphoblastic Leukemia-Lymphoma Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Other Conditions

Leukemia, Lymphoblastic, Acute Leukemia, Lymphoblastic, Acute, T Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Acute, Childhood

Stopping Reasons

Enzon Pharmaceuticals decided to end its development of EZN-3042.

Limitations And Caveats

The study was terminated early because Enzon Pharmaceuticals decided to halt development of EZN-3042.

Result Publications


Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID